These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3363660)

  • 21. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated.
    Ehrich JH; Geerlings C; Zivicnjak M; Franke D; Geerlings H; Gellermann J
    Nephrol Dial Transplant; 2007 Aug; 22(8):2183-93. PubMed ID: 17504846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution.
    Venkataramanan R; Burckart GJ; Ptachcinski RJ; Blaha R; Logue LW; Bahnson A; Giam CS; Brady JE
    Am J Hosp Pharm; 1986 Nov; 43(11):2800-2. PubMed ID: 3799618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporine in the therapy of steroid-resistant idiopathic nephrotic syndrome.
    Niaudet P; Fuchshuber A; Gagnadoux MF; Habib R; Broyer M
    Kidney Int Suppl; 1997 Mar; 58():S85-90. PubMed ID: 9067953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosporine treatment of nephrotic syndrome in children.
    Brodehl J; Hoyer PF; Oemar BS; Helmchen U; Wonigeit K
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):269-74. PubMed ID: 3381282
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of cyclosporine in idiopathic nephrotic syndrome resistant to immunosuppressive therapy.
    Erbay B; Karatan O; Duman N; Ertuğ AE
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):289-92. PubMed ID: 3381285
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pharmacokinetics and metabolism of cyclosporin; drug interactions].
    Le Bigot JF; Lavene D; Kiechel JR
    Nephrologie; 1987; 8(3):135-41. PubMed ID: 3658089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction between cyclosporine and acenocoumarol in a patient with nephrotic syndrome.
    Borrás-Blasco J; Enriquez R; Navarro-Ruiz A; Martinez-Ramirez M; Cabezuelo JB; Gonzalez-Delgado M
    Clin Nephrol; 2001 Apr; 55(4):338-40. PubMed ID: 11334326
    [No Abstract]   [Full Text] [Related]  

  • 28. Ocular bioavailability of cyclosporine after oral administration.
    Tabbara KF; Gee SS; Alvarez H
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):656-9. PubMed ID: 3363663
    [No Abstract]   [Full Text] [Related]  

  • 29. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children.
    Salomon R; Gagnadoux MF; Niaudet P
    Transplantation; 2003 Mar; 75(6):810-4. PubMed ID: 12660507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporine A for treatment of nephrotic syndromes.
    Brandis M; Burghard R; Leititis J; Zimmerhackl B; Hildebrandt F; Helmchen U
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):275-9. PubMed ID: 3381283
    [No Abstract]   [Full Text] [Related]  

  • 31. The pharmacokinetics of cyclosporine A in uremic patients.
    Lindberg A; Odlind B; Tufveson G; Lindström B; Gabrielsson J
    Transplant Proc; 1986 Dec; 18(6 Suppl 5):144-52. PubMed ID: 3787709
    [No Abstract]   [Full Text] [Related]  

  • 32. Cyclosporine experience in nephrotic syndrome.
    Phadke K; Ballal S; Maiya V
    Indian Pediatr; 1998 Feb; 35(2):111-6. PubMed ID: 9707852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The chemical and immunosuppressive stability of cyclosporine during continuous intravenous infusion.
    Atkinson K; Britton K; Farrell C; Biggs JC
    Transplantation; 1983 Nov; 36(5):590-2. PubMed ID: 6227115
    [No Abstract]   [Full Text] [Related]  

  • 34. A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytonadione (vitamin K(1)).
    Riegert-Johnson DL; Kumar S; Volcheck GW
    Bone Marrow Transplant; 2001 Dec; 28(12):1176-7. PubMed ID: 11803365
    [No Abstract]   [Full Text] [Related]  

  • 35. [The effect of treatment methods on frequency of relapse in nephrotic syndrome in children].
    Goszczyk A; Jung A; Bochniewska V; Straz-Zebrowska E
    Pol Merkur Lekarski; 2000 Sep; 9 Suppl 1():25-6. PubMed ID: 11081338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The plasma time course of orally-administered cyclosporine in the dog.
    Buice RG; Gurley BJ; Sidhu P
    Res Commun Chem Pathol Pharmacol; 1985 Oct; 50(1):143-6. PubMed ID: 4081308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous cyclosporine and kidney function: the Johns Hopkins experience.
    Williams GM; Irwin B; Burdick J; Pennington L
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):66-8. PubMed ID: 3515697
    [No Abstract]   [Full Text] [Related]  

  • 38. Anaphylactic reaction and cardiopulmonary arrest following intravenous cyclosporine.
    Friedman LS; Dienstag JL; Nelson PW; Russell PS; Cosimi AB
    Am J Med; 1985 Feb; 78(2):343-5. PubMed ID: 3970058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection.
    Ptachcinski RJ; Logue LW; Burckart GJ; Venkataramanan R
    Am J Hosp Pharm; 1986 Jan; 43(1):94-7. PubMed ID: 3953588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporine disposition in the dog. Comparison of radioimmunoassay with high-performance liquid chromatographic assay and pharmacokinetics following intravenous administration.
    Buice RG; Gurley BJ; Stentz FB; Sidhu P; McClellan T; Williams JW
    Transplantation; 1985 Nov; 40(5):483-8. PubMed ID: 4060219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.